FDA Inspection
Lilly del Caribe, IncLilly del Caribe, Inc – FDA Inspection, Feb 25, 2022
Record Details
This FDA Inspection record concerns Lilly del Caribe, Inc, with an inspection on February 25, 2022, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Lilly del Caribe, Inc
- Inspection Date
- February 25, 2022
- Product Type
- Drugs
View Company Profile
ID · 67a137fe-39cd-4944-a803-b07d21b0597d
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1163359
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
2- 21 CFR 211.192Extent of discrepancy, failure investigations
- 21 CFR 211.160(b)Scientifically sound laboratory controls
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Lilly del Caribe, Inc
8| Date | Classification | Office | Project area |
|---|---|---|---|
| January 30, 2026 | VAI | San Juan District Office | Drug Quality Assurance |
| February 16, 2024 | Not classified | San Juan District Office | |
| July 12, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 21, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 21, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Lilly del Caribe, Inc
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.